Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Paris, France, 4^th May 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will be presented at the 2022 American Society of Cell & Gene Therapy (ASCGT) meeting, which will be held virtually and in person in Washington, D.C., 16 to 19 May.

The poster presentation entitled ‘Chemically engineered AAV vectors to improve biodistribution and gene transfer to the central nervous system’ will highlight important pre-clinical data about the company’s proprietary ALIGATER platform, showing it can transform standard AAVs into more potent vectors to treat diseases that affect large and/or deep structures of the brain.

Poster details at the ASGCT 25th Annual Meeting

• Abstract Title: Chemically engineered AAV vectors to improve biodistribution and gene transfer to the central nervous system
• Abstract Number: 994 / Poster Board Number: W-120
• Poster Session: Synthetic/Molecular Conjugates and Physical Methods for Delivery II
• Room: Hall D
• Date & Time: Wednesday 18 May at 17:30 ET

Presenter: Gaelle Lefevre, Head of Discovery Sciences at Coave Therapeutics